Keytruda for classical Hodgkin lymphoma, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma ( cHL ), or those who have relapsed after three or more prior lines of therapy.
Approval was based on data from 210 adult patients with classical Hodgkin lymphoma enrolled in a multicenter, non-randomized, open-label clinical trial.
Patients had refractory or relapsed disease after autologous stem cell transplantation ( ASCT; 129 patients ) and/or Brentuximab vedotin ( 175 patients ), and received a median of four prior systemic therapies ( range: 1, 12 ).
With a median follow-up of 9.4 months ( range: 1-15 ), the overall response rate was 69% ( 95% CI: 62, 75 ). This included partial responses in 47% of patients and complete responses in 22%.
The estimated median response duration was 11.1 months ( range 0+ to 11.1 ).
Efficacy in pediatric patients was extrapolated from results observed in adults.
Safety was evaluated in 210 adults with classical Hodgkin lymphoma. In adults, the most common ( at least 20% ) adverse reactions were fatigue, pyrexia, cough, musculoskeletal pain, diarrhea, rash and hypertransaminasemia.
Additional common adverse reactions ( at least 10% ) included dyspnea, arthralgia, vomiting, nausea, pruritus, hypothyroidism, upper respiratory tract infections, headache, peripheral neuropathy, hyperbilirubinemia and increased creatinine.
Other immune-mediated adverse reactions occurring in 0.5-9% of patients included infusion reactions, hyperthyroidism, pneumonitis, uveitis, myositis, myelitis and myocarditis.
Fifteen percent had an adverse reaction requiring systemic corticosteroid therapy.
Pembrolizumab was discontinued due to adverse reactions in 5% of patients, and treatment was interrupted due to adverse reactions in 26%.
Safety was also evaluated in 40 children with advanced melanoma, PD-L1 positive solid tumors, or lymphoma.
The safety profile in the pediatric patients was similar to that observed in adults.
Adverse reactions occurring at a higher rate ( difference of 15% or greater ) in children than adults included fatigue, vomiting, abdominal pain, hypertransaminasemia and hyponatremia.
Pembrolizumab exposure in these pediatric patients at a dose of 2 mg/kg every 3 weeks was comparable to that seen in adults. FDA has required the sponsor to evaluate Pembrolizumab’s long-term safety in pre-pubertal patients, and those who have not completed pubertal development.
A new Warning and Precaution was added for complications of allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) after Pembrolizumab.
Transplant-related deaths have occurred, and health care professionals should follow patients closely for early evidence of transplant-related complications, such as hyperacute graft-versus-host-disease ( GVHD ), severe ( grade 3 to 4 ) acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease ( VOD ), and other immune-mediated adverse reactions.
FDA has required the sponsor to further study the safety of allogeneic HSCT after Pembrolizumab therapy.
The recommended dose and schedule of Pembrolizumab for classical Hodgkin lymphoma is 200 mg every 3 weeks for adults and 2 mg/kg ( up to 200 mg ) every 3 weeks for pediatric patients. ( Xagena )
Source: FDA, 2017
The FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) tablets for the acute treatment...
Tthe FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) an oral medication for the...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients...
The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...
Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...
CAR-T cell therapy, Kymriah for B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma: approved in European Union
The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the...
FDA has approved Tibsovo, the first targeted treatment, for patients with relapsed or refractory acute myeloid leukemia with mutations in the IDH1 gene
The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of...
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...
Xospata for adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Xospata ( Gilteritinib ) tablets for the treatment of...